- Home
- ORIC vs PHAR Comparison
ORIC vs PHAR Comparison
Compare ORIC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | PHAR |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ORIC | PHAR |
|---|---|---|
| Price | $11.00 | $16.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $18.78 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 1.2M | 23.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $24.80 |
| Revenue Next Year | N/A | $6.84 |
| P/E Ratio | ★ N/A | $2,942.01 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $3.90 | $7.50 |
| 52 Week High | $14.93 | $17.86 |
Technical Indicators
Market Signals| Indicator | ORIC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 54.58 |
| Support Level | $10.45 | $15.76 |
| Resistance Level | $12.14 | $17.67 |
| Average True Range (ATR) | 0.77 | 0.79 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 26.05 | 48.57 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.